Gefitinib (ZD1839)

Catalog No.S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Cited by 189 Publications

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )
DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )
Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )
Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )
PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )
Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )
Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )
Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	NFq2T3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfrTWM2OD1yLkC1OEDPxE1?	NXr2[npEOTZ3MU[0O\|M>
NIH3T3	M4f4e2Z2dmO2aX;uJGF{e2G7	MoP2NE4zKM7:TR?=	M{jvdlIhcA>?	NGXNW5RFVVOR	MnHCTY5pcWKrdHnvckBw\iCHR1[gd5RqdXWuYYTl[EBpfW2jbjDldoJDOSCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNESg{txO	MXWxOlQ5ODJ6NB?=
COS7	M4C0c2Z2dmO2aX;uJGF{e2G7	M3jr[\|k3KM7:TR?=			M4PEVWlvcGmkaYTpc44hd2ZiaIXtZY4hUkGNMjDWOlE4TiCvdYThcpQh\XiycnXzd4Vl	M4Pze\|E4OTd6N{Ky
A549	MVHDfZRwfG:6aXOgRZN{[Xl?		MlHFPVYhcA>?	NGfReGRFVVOR	Mnf1TWM2OD1zMz61PUDPxE1?	NIm1dGQyQDNzM{iwOy=>
K562	MnSwR5l1d3SxeHnjJGF{e2G7		MlTTPVYhcA>?	M4XvUWROW09?	MUHJR\|UxRTlwM{[g{txO	NUnyWVExOTh\|MUO4NFc>
MDA-MB-231	NFrO[IZEgXSxdH;4bYMhSXO\|YYm=		NYHQd\|NEQTZiaB?=	NV21Z3V[TE2VTx?=	M1X2RWlEPTB;M{[uOlEh\|ryP	MX[xPFMyOzhyNx?=
MOLT4	MnjQR5l1d3SxeHnjJGF{e2G7		M{Tq[Vk3KGh?	MlrESG1UVw>?	NXrpeYtKUUN3ME2xOU4xOiEQvF2=	NITnPI0yQDNzM{iwOy=>
MCF7	NYH5T\|hWS3m2b4TvfIlkKEG\|c3H5	MWO1NEDPxE1?	NVjmWpYxPzJiaB?=		NHHHSZlKSzVyPUGyMlA2KM7:TR?=	NGLhcHMyQDd5MUixPS=>
BT474	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWXpdXNEPzJiaB?=		MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEKWNEe0JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWUQnKyJJdqfGhiRVO1NEBw\iByLkOg{txO	MojuNVkxOjh2MkS=
HN5	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX;aSo5[PzJiaB?=		M37IemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSF61JINmdGy\|IH;2[ZJmgHC{ZYPzbY5oKEWJRmKge4l1cCCHQ{WwJI9nKDBwMEGg{txO	NHzEW5YyQTB{OESyOC=>
BA/F3	MVTDfZRwfG:6aXOgRZN{[Xl?		NUDxTGVLPzJiaB?=		NWnqeldCS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSJI12fGGwdDD3bZRpKEmFNUCgc4YhOC5yMUC4JO69VQ>?	NWfaUIVjOTl{M{myNlk>
NIH3T3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEj6c2I4OiCq		M1vkPGdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJG5KUC9\|VEOgZ4VtdHNiZYjwdoV{e2mwZzDldmIzKGenbnWge4l1cCCLQ{WwJI9nKDBwNUSg{txO	NUXHV\|lFOTl4NkWzO\|c>
MCF7 MX	NHvyRW1HfW6ldHnvckBCe3OjeR?=		MlvDN\|AhdWmw		NHvkO5pKdmirYnn0bY9vKG:oIFLDVnAh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxMlEh\|ryP	NV;aWGdQOTl7M{K5OlA>
A431	M17pVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrWc4FsOTBizszN	M1XqbFczKGh?		NW\mV5l2T0l3ME2wMlUyPCEQvF2=	M3TRTFE6QTZ7NE[1
A431	MkTnT4lv[XOnIFHzd4F6	MXuwMlEh\|ryP	NV\2R4RtOSCq		M3fp[mlvcGmkaYTpc44hd2ZiRVfGMYlv\HWlZXSgSWdHWiCyaH;zdIhwenmuYYTpc44>	NIHaOVMyQTl4OUS2OS=>
A431	NGLUcppMcW6jc3WgRZN{[Xl?	NEPke2MyODBizszN	NWf4TXRJOTBibXnu		NFe1UHFRem:ub37n[YQhcW6qaXLpeI9zgSCjY4Tpeol1gSCxZjDFS2YucW6mdXPl[EBGT0[UIIDoc5NxcG:{eXzheIlwdg>?	NVT4R2xyOTl7Nkm0OlU>
Sf9	Mke5T4lv[XOnIFHzd4F6		NF;JR4syOCCvaX6=	NEDB[WJFVVOR	NEHrZXJKdmirYnn0bY9vKG:oIFXHSnIh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemWlZYD0c5Ih[XW2b4Doc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xOzNizszN	NYXaNFliOjByNU[0NlU>
NCI-H1975	NFXYOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2P4fFUh\|ryP	NXGzOVFjPzJiaB?=		MXzJR\|UxRThwMk[g{txO	NFW3bpAzODF3MU[3NC=>
NCI-H1975	NGDCdZNMcW6jc3WgRZN{[Xl?	MYWxNEDPxE1?			NHvET\|dKdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	NHGzUmQzODF3MU[3NC=>
NCI-H1975	NWSyUVRXTnWwY4Tpc44hSXO\|YYm=	MYKxNEDPxE1?			MmjmTY5pcWKrdHnvckBw\iCHUlLCNkBifXSxcHjvd5Bpd3K7bHH0bY9v	M{LnUlIxOTVzNkew
NCI-H1975	M4j1WmZ2dmO2aX;uJGF{e2G7	MlLxOUDPxE1?	M{jyUVQ5KGh?		M3fr[Wlv\HWldHnvckBw\iCjcH;weI9{cXNiYYPz[ZN{\WRiYYOgZYN1cX[jdHnvckBw\iClYYPwZZNmNTN?	MUiyNFE2OTZ5MB?=
A375	NYLUfIliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXy0PEBp		NVvvenVlUUN3ME2yNE42PSEQvF2=	MWGyNFMxPDV\|Nx?=
SMMC7721	NFTxb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkOyOFghcA>?		M3zR[mlEPTB;M{OuNVIh\|ryP	MXSyNFMxPDV\|Nx?=
DU145	MVLDfZRwfG:6aXOgRZN{[Xl?		NIH1boE2KGR?	MmjZSG1UVw>?	MVHJR\|UxRTR{LkG3JO69VQ>?	NYHJTGlYOjB2Nk[1OVU>
MIAPaCa2	NVTvXVFHS3m2b4TvfIlkKEG\|c3H5		Mn\wOUBl	Mk\CSG1UVw>?	M4XkcGlEPTB;NUCuOlIh\|ryP	NUDzfWR2OjB2Nk[1OVU>
PANC1	MojCR5l1d3SxeHnjJGF{e2G7		NV\5XlQ3PSCm	MXfEUXNQ	MYTJR\|UxRTRyLkSyJO69VQ>?	M1LJSVIxPDZ4NUW1
PC9	NEXQNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnr5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDFS2ZTNWSnZnnjbYVvfCCqdX3hckBRSzliY3XscJMhf2m2aDDFR\|UxKG:oIECuNFE4KM7:TR?=	MlLONlEzODh6MEK=
PC9	NHfiV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHfyc5d1cC2{ZYPpd5RidnRiaIXtZY4hWEN7IHPlcIx{KGW6cILld5NqdmdiRVfGVkBGPzR4X1G3OVAwXDd7MF2gcZV1[W62IIfpeIghTUN3MDDv[kA4KM7:TR?=	MorLNlEzODh6MEK=
PC3	MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnFWGU3OTBizszN	NES1NIU4OiCq	MYPEUXNQ	MX3JR\|UxRTdwNDFOwG0>	M2r2PVIyOzV\|NUS2
MDA-MB-468	M{\0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTkNVAxKM7:TR?=	M3;NXlQ5KGh?	NYfyd4hOTE2VTx?=	NGPzTlFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fS=>	MmHzNlE1Ojl4M{K=
Plasmodium falciparum					MojHdWhVWyCycn;mbYxqdmdiZn;yJIlvcGmkaYTvdpMhd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJJBzd2yrZnXyZZRqd25?	NHqxdI0zOThzN{C0OS=>
NCI-H1993	NXzoRpAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY[3NkBp	Mn7WSG1UVw>?	M4H3OWlEPTB;MD6xJO69VQ>?	MVOyNVkyPjR\|Mx?=
NCI-H292	NGHJOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYq3NkBp	MX7EUXNQ	Mm\sTWM2OD1yLkCyJO69VQ>?	MoT5NlE6OTZ2M{O=
A431	Ml\wT4lv[XOnIFHzd4F6		MV6yJIg>	MYTEUXNQ	M{LTUmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iQUSzNUB4cXSqIFnDOVAhd2ZiMD6wNFEh\|ryP	NXnHfY5wOjJzMEGxN\|I>
MCF7	NEP2cJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUmxNFDDqM7:Zz;tUC=>	NUTvfWhuPDhiaB?=	M{Tnc2ROW09?	NIPsOVlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkBo\W6nIIfpeIghUUN3MDDv[kAyOi5yNTFOwG0>	MnzxNlIyOTlzM{C=
BT474	NUHte2tsS3m2b4TvfIlkKEG\|c3H5	MnLJNVAh\|ryP	MlPLOFghcA>?		MY\DfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKEKWNEe0JINmdGy\|	MnL5NlIyOzh\|MEi=
MCF7	NUHMRZlNS3m2b4TvfIlkKEG\|c3H5	MVKxNEDPxE1?	M3LlblQ5KGh?		NEW2e4ZEgXSxdH;4bYNqfHliYXfhbY5{fCC\|ZYL1cU1{fGG{dnXkJIh2dWGwIF3DSlch[2WubIOgc5Zmei2neIDy[ZN{cW6pIFXyZmIzKGOnbHzz	MVmyNlE{QDNyOB?=
HCC827	NHn2cFBMcW6jc3WgRZN{[Xl?	MXGwMlEzPSEQvF2=	NX\SbmtiOjRiaB?=	NEDO[25FVVOR	M3rBbmlvcGmkaYTpc44hd2ZiRVfGVkBl\WxiRUe0Ok1CPzVyIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9v	MXeyNlM{QTN2Mh?=
HCC827	NYDqelRRU2mwYYPlJGF{e2G7	M{TrVlAvOTJ3IN88US=>	MVmyOEBp	NWDQVXlxTE2VTx?=	NEHCVnlKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=	M2j5WFIzOzN7M{Sy
HCC827	MXnLbY5ie2ViQYPzZZk>	MWqwMlEzPSEQvF2=	MWKyOEBp	NUjHVZFsTE2VTx?=	NVPxSWdmUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62LX3l[IlifGWmIFHreEBxcG:\|cHjvdplt[XSrb36=	NGPvTIYzOjN\|OUO0Ni=>
A431	NGnFeoVMcW6jc3WgRZN{[Xl?	MWKxNFAh\|ryP	Mk\UN\|AhdWmw		NFnaWnpKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	NUnkOVUyOjJ4OUi3PFI>
H460	MlT5R5l1d3SxeHnjJGF{e2G7		M4TYOlczKGh?		M2TwN2lEPTB;NT61PUDPxE1?	NWnJbIxFOjJ5Mke0OFk>
HT-29	M2TiXWN6fG:2b4jpZ{BCe3OjeR?=		NWr5[5pYPzJiaB?=		Mmf5TWM2OD1\|LkO2JO69VQ>?	NVrv[ZpiOjJ5Mke0OFk>
SGC7901	MW\DfZRwfG:6aXOgRZN{[Xl?		NIHJO2U4OiCq		NUPzVXRmUUN3ME2xNE4zPiEQvF2=	MXeyNlczPzR2OR?=
A498	NFKzO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLNbmFVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFk5KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhcoQhW1KFIIfpeIghUUN3MDDv[kA5NjZizszN	Ml\vNlI5OTh6NEi=
Calu3	NWXSSpBsS3m2b4TvfIlkKEG\|c3H5	NXfBR\|h4OTBizsznM41N	MVO3NkBp		NIDBN4NKSzVyPUGuOkDPxE1?	MmG1NlMyOTZzNki=
FADU	MWnDfZRwfG:6aXOgRZN{[Xl?	NVnpc3J4OTBizsznM41N	MV[3NkBp		MnfMTWM2OD1yLkC1JO69VQ>?	NHzKWJgzOzFzNkG2PC=>
HCC827	NWGxSIg3S3m2b4TvfIlkKEG\|c3H5	MX:xNEDPxGdxbVy=	MYK3NkBp		MkLTTWM2OD1yLkCwNVUh\|ryP	MWSyN\|EyPjF4OB?=
PC9	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13YN\|ExKM7:Zz;tUC=>	MUi3NkBp		MW\JR\|UxRTBwMEG0JO69VQ>?	MlqyNlMyOTZzNki=
Sf9	NX;FUVdkU2mwYYPlJGF{e2G7		NV;tZ5hzOSCq	M1T5bWROW09?	NGP4[\|NKdmirYnn0bY9vKG:oIHj1cYFvKEeVVD30ZYdo\WRiRVfGVkBNQDN2UjDteZRidnRiZYjwdoV{e2WmIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0>	MXqyN\|YyOTZ7MR?=
16HBE14o-	MVTDfZRwfG:6aXOgRZN{[Xl?	NEflWpMyOCEQvF2=	MWe3NkBp	M2rDOWROW09?	NGn5[\|hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckAyPkiERUG0c{0h[2WubIOgbIFz[m:{aX7nJJdqdGRidInw[UBGT0[UIHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJJdqfGhiSVO1NEBw\iBzMj63NUDPxE1?	MlfFNlM3Pjh2NEG=
NCI-H1975	MYHDfZRwfG:6aXOgRZN{[Xl?	NWf5dJBkOTBizszN	MYe3NkBp	Mo[ySG1UVw>?	NWm4N2dIS3m2b4TvfIlkcXS7IHHnZYlve3RiZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEe5NG0h\G:3YnzlJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiNj65NVch\|ryP	NGW3T2UzOzZ4OES0NS=>
16HBE	NVX3NZNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWK3NkBp	MljzSG1UVw>?	NYW1RnRpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjCxOmhDTSClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHR1\SJJdqfGhiSVO1NEBw\iBzLk[wNUDPxE1?	MY[yN\|c6OjNzOB?=
16HBE	M1SzVGZ2dmO2aX;uJGF{e2G7	MYmxNFAh\|ryP	MXSxOVAhdWmw	M4\DcmROW09?	M3OybGlv\HWldHnvckBw\iCwaYTybYMhd3irZHWgdJJw\HWldHnvckBqdiCqdX3hckAyPkiERTDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFS2ZT	M{fRe\|I{Pzl{M{G4
A549	NWjVPWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYW3NkBp	MX3EUXNQ	NXnmb4hMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhTUeIUj;rMXJieyCmZYDlcoRmdnRiaIXtZY4hSTV2OTDj[YxteyC5aYToJGlEPTBib3[gOE43OjZizszN	M{LlfFI{Pzl{M{G4
SH-SY5Y	NFjtV4FEgXSxdH;4bYMhSXO\|YYm=		NIXRfYY4OiCq		MnG3TWM2OD1zOD6yNUDPxE1?	M1f5PVI{QDdzOUC5
LoVo	M{izd2tqdmG\|ZTDBd5NigQ>?		NUPuVpZtOiBiaB?=	NHXOcFRFVVOR	MkK3TY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yNkKg{txO	NHvhS2czOzl\|MEm5OC=>
PC9	NInIVGdMcW6jc3WgRZN{[Xl?		NVTyc4dIOiCq	NYDRc5RGTE2VTx?=	Mmj3TY5pcWKrdHnvckBw\iCHR1\SJIV5d25iMUmg[IVt\XSrb36gZYN1cX[jdHnu[{BufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGDDPUBk\WyuczD3bZRpKEmFNUCgc4YhOC5yMEi3JO69VQ>?	MWCyN\|k{ODl7NB?=
HCC827	NWq0O2p1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHjLXIE4OiCq		MoPmTWM2OD1yLkCxNkDPxE1?	M3i0PFI{QTd\|MU[4
A549	M{fJXmtqdmG\|ZTDBd5NigQ>?	MVyxJO69VQ>?	MUexJIg>	M2LBTGROW09?	NVrqd5NLUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN7OTFOwG0>	MoSwNlM6QDh\|NUS=
A549	M37rSGZ2dmO2aX;uJGF{e2G7	NGjL[IcyKM7:TR?=	NUf0cpJDOSCq	MWLEUXNQ	MVTD[YxtfWyjcjD1dJRic2V?	M3PjV\|I{QTh6M{W0
HCC827	MlvrT4lv[XOnIFHzd4F6	NHTiWWQxNjVizszN	NF76XpozKGh?	M17o[mROW09?	M4XvPGlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4h\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHN?	M4\uTlI{QTl\|M{K4
HCC827	MljaSpVv[3Srb36gRZN{[Xl?	M2\4NlAvPSEQvF2=	NV;lPWlJOiCq	NGjU[YVFVVOR	NV\3cYtoUW6qaXLpeIlwdiCxZjDjMW1mfCCyaH;zdIhwenmuYYTpc44hcW5iZ3XmbZRqdmmkLYLld4l{fGGwdDDoeY1idiCKQ1O4Nlch[2WubIO=	M3LYbVI{QTl\|M{K4
HCC827	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPqcnRFOTBizszN	MV63NkBp	NYPD[oxlTE2VTx?=	MnTQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDn[YZqfGmwaXKtd4Vve2m2aY\lJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3KHSxIFG3OVAh\GWuZYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2QDFizszN	NWXqZm9XOjRyNUO2O\|Q>
A431	NGHvbHNMcW6jc3WgRZN{[Xl?	M1rwRVExOCEQvF2=	MWezNEBucW5?		M4C0[WlvcGmkaYTpc44hd2ZiRVfGVkBqdiC\|aHXkJI1mdWK{YX7lJJZme2mlbHXzJJdqfGhiSVO1NEBw\iBzLkGg{txO	NFXWOYkzPDB7NESzNi=>
BCRP-MDCK2	M2\qOmZ2dmO2aX;uJGF{e2G7	NWjEZYR7OS56IN88US=>	MlvHO\|IhcA>?	Mni5SG1UVw>?	M4C3TGlv[3KnYYPlJI9nKHCuYYPtZUBu\W2kcnHu[UBmgHC{ZYPzbY9vKG:oIFLDVnAh\XiycnXzd4lv\yC{ZYDvdpRmeiCpZX7lJGdHWA>?	NIDxfmIzPDF6NEKxNy=>
BCRP-MDCK2	NGW3XmZHfW6ldHnvckBCe3OjeR?=	NECzTYYyNjhizszN	MUe3NkBp	NVfNc4djTE2VTx?=	NX;iTJdPWmWmdXP0bY9vKG:oIIDsZZNu[SCvZX3idoFv\SCneIDy[ZN{cW:wIH;mJGJEWlBiZYjwdoV{e2mwZzDy[ZBwenSncjDn[Y5mKEeIUB?=	NX;2OYQ{OjRzOESyNVM>
MDCK	NIe3[5FEgXSxdH;4bYMhSXO\|YYm=		M3HWfFczKGh?	NGD6bItFVVOR	MWDHTVUxRTFwNEWg{txO	MlG3NlQyQDR{MUO=
MDCK2	NIrWXINHfW6ldHnvckBCe3OjeR?=	NFLVepQyNjhizszN	M1vOfFczKGh?	MoHxSG1UVw>?	NXK2eJhsUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2LQJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCKb3XjbJN1KDN\|M{SyJIFk[3WvdXzheIlwdiC5aYToJGlEPTBib3[gN{4yQSEQvF2=	M2qyVVI1OTh2MkGz
A431	MoTqR5l1d3SxeHnjJGF{e2G7		MXO3NkBp	NYW1cIRLTE2VTx?=	M3[4VWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh\XiycnXzd4lv\yCHR1\SJJdqfGhiSVO1NEBw\iByLkW1JO69VQ>?	MW[yOFQyOTF{Mx?=
Calu3	Moe5R5l1d3SxeHnjJGF{e2G7		NVnGUY1YPzJiaB?=	NUnWSWJHTE2VTx?=	M3XSVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNidHV\|IHPlcIx{KGW6cILld5NqdmdiSFXSNkB4cXSqIFnDOVAhd2ZiMD65PUDPxE1?	NGXzWZQzPDRzMUGyNy=>
KB	MYfLbY5ie2ViQYPzZZk>	M2G3WlExKM7:TR?=	NIPJXXMyKGh?	M3\1ZWROW09?	NV3FWpo{UW6qaXLpeIlwdiCxZjDFS2Yue3SrbYXsZZRm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJid3n0bEBKSzVyIH;mJFAvODJ3IN88US=>	NGm2eHQzPDRzMUGyNy=>
BEAS2B	NGHWSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml31OVAh\|ryP	MnzQO\|IhcA>?	MVLEUXNQ	M2PkUGlEPTB;MUOuPVQh\|ryP	M3XaflI1PjB5NUmx
NCI-H1975	M33OemZ2dmO2aX;uJGF{e2G7	M3voWlExOCEQvF2=	MmXVNVUxKG2rbh?=	MmXYSG1UVw>?	M3PwZ2lv\HWldHnvckBw\iCQTzDwdo9lfWO2aX;uJIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	M1mycVI1PjB5NUmx
Hela	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUnQbIF1OjRiaB?=	MWPEUXNQ	MUDJR\|UxRTJwNkeg{txO	NYT4RnhZOjR5M{GyPFE>
HepG2	NILzZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYnoZW5bOjRiaB?=	M{HCU2ROW09?	MWLJR\|UxRTZwNEKg{txO	NVvkNXBJOjR5M{GyPFE>
Sf9	MonVT4lv[XOnIFHzd4F6		MUCxNEBucW5?	NV;uZoFKTE2VTx?=	NXHK[nRHUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKHKnY3;tZolv[W62IHjpd{11[WepZXSgSWdHWiBqYX3pco8h[WOrZDC2OFUuOTF6Njmg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>?	NYDpbVN3OjR5M{GyPFE>
SW620	NHnublBEgXSxdH;4bYMhSXO\|YYm=		Mn;vOFghcA>?	M1rweGROW09?	MWjJR\|UxRTJ6LkKg{txO	Mn3oNlQ6ODB3OUS=
HCC827	MoLxSpVv[3Srb36gRZN{[Xl?	NWHVfHBKOC53IN88US=>	NFKwVIEzKGh?	NVXQW2E{TE2VTx?=	MlLs[I9meyCwb4SgbY5pcWKrdDDjMW1mfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25?	NFewVXEzOzl7M{OyPC=>
HCC827	NYX1PVdRTnWwY4Tpc44hSXO\|YYm=	M3HobFAvPSEQvF2=	NHPIW5UzKGh?	NXrWdGhxTE2VTx?=	NW\2OFJH\G:nczDuc5QhcW6qaXLpeEBkNU2ndDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIC0OE81OiCyaH;zdIhwenmuYYTpc44>	M3SyXVI{QTl\|M{K4
HCC827	NHPjeGREgXSxdH;4bYMhSXO\|YYm=	MkLJNE42KM7:TR?=	NUj1OIZTPzJiaB?=	M2DJNmROW09?	NI[yTpRp[XNibn:gZ5l1d3SxeHnjbZR6	NUfLRodrOjN7OUOzNlg>
NCI-H1975	M1jQOWZ2dmO2aX;uJGF{e2G7	M3HPeVExKM7:TR?=	NUjYR48xQCCq	MWrEUXNQ	MnvY[I9meyCwb4SgbY5pcWKrdHmgSWdHWiCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hTVKNIIDoc5NxcG:{eXzheIlwdg>?	Ml;PNlMyOTZzNki=
A431	M4DnZmtqdmG\|ZTDBd5NigQ>?	NUnLdJZMOSEQvF2=	NVjqcVV3OSCq	MYLEUXNQ	MonDbIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	M4fBelI1QTByNUm0
LNCaP	MoX4SpVv[3Srb36gRZN{[Xl?	M1jSb\|ExKM7:TR?=	M{XUZlJpKG:{IESgbC=>	MkLoSG1UVw>?	NGrYTGFld2W\|IH7veEBqdmirYnn0JIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiaX3teY5weHW{aX\p[YQh\myjZz30ZYdo\WRiQn34JIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzN{UG3BWHA>	MWqxPFY3PzNzMh?=
H1975	M{LF[2tqdmG\|ZTDBd5NigQ>?	MWexJO69VQ>?	NXHmTHpMOjRiaB?=	MmjJSG1UVw>?	M3TtfYRw\XNibn;0JIlvcGmkaYSgSWdHWiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	NIT3W2szPDZyN{W5NS=>
H1975	MnnXSpVv[3Srb36gRZN{[Xl?	NUjVVlNtOSEQvF2=	M4PDU\|I1KGh?	M2DpS2ROW09?	NWO2U21H\G:nczDuc5QhcW6qaXLpeEBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCP	M4KyTlI1PjB5NUmx
HCC827	M4\LZWtqdmG\|ZTDBd5NigQ>?	NGqwUFExNjFzIN88US=>	MkHHNUBp	Mmi1SG1UVw>?	M3r3NohieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG\|c3Xzd4VlKGG\|IILlZ493\XK7IH;mJGVITlJiYYX0c5Bpd3OyaH;yfYxifGmxbh?=	MWmyOFEzPDh7OB?=
H1975	NHPTc2NMcW6jc3WgRZN{[Xl?	MVSwMlM{KM7:TR?=	NFTKc5czKGh?	MXnEUXNQ	M2ryOoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBCU1RicHjvd5Bpd3K7bHH0bY9v	NH;6blIzPDF{NEi5PC=>
H1975	M2Cze2tqdmG\|ZTDBd5NigQ>?	Mn[zNE4{OyEQvF2=	NXrTN5FVOiCq	MUjEUXNQ	MlTP[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGVTUyCyaH;zdIhwenmuYYTpc44>	MoPQNlQyOjR6OUi=
H1975	MWrLbY5ie2ViQYPzZZk>	MkH5NE4{OyEQvF2=	NXHKR5oxOiCq	NFvhZpZFVVOR	NEfXUJhld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCyaH;zdIhwenmuYYTpc44>	MnP3NlQyOjR6OUi=
H1975	NE\Ve4lMcW6jc3WgRZN{[Xl?	MlTPNE4yOjVizszN	M1Hl[lI1KGh?	M{TFWGROW09?	M1XsNYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRiWUGwOlgh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MUmyNlM{QTN2Mh?=
H1975	MlXHT4lv[XOnIFHzd4F6	NYHVTZJNOC53IN88US=>	NHzUR\|MzPCCq	NIPGempFVVOR	MmDq[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfC2vZXTpZZRm\CCHcnugdIhwe3Cqb4L5cIF1cW:w	Mn3iNlI{Ozl\|NEK=
H1975	M2C4TGtqdmG\|ZTDBd5NigQ>?	NYn2bnZDOC53IN88US=>	NH7pWJUzPCCq	NXrFcWJbTE2VTx?=	M1fSeoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	MlTzNlI{Ozl\|NEK=
MIAPaCa2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\aNk42KM7:TR?=	M{jNblczKGh?	MWjEUXNQ	NX;uOIp7cGG\|IH7vJIdzd3e2aDDpcohq[mm2aX;u	MkPsNlA1PjZ3NUW=
MIAPaCa2	NEnYUFFEgXSxdH;4bYMhSXO\|YYm=	M3XWWlEh\|ryP	MWixNEBl	MWXEUXNQ	NV3pZ2lIcGG\|IH7vJIN6fG:2b4jpZ4l1gSCjc4Pld5Nm\CCjczDzeZBxemW\|c3nvckBw\iClb3zvcpkh\m:{bXH0bY9v	MlztNlA1PjZ3NUW=
MIAPaCa2	NUP2eZlbSXCxcITvd4l{KEG\|c3H5	Mnf5NVAh\|ryP	NEXyXYszPGhib4KgOFghcA>?	M17aTWROW09?	NFzRVIJld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	NYr3XppbOjB2Nk[1OVU>
MIAPaCa2	M4\ofGFxd3C2b4Ppd{BCe3OjeR?=	NFnCNnAzOCEQvF2=	MWCyOEBp	NEDYOo1FVVOR	M3LRUIRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMh[2G\|cHHz[UA{KGGldHn2ZZRqd25?	NUewTYhrOjB2Nk[1OVU>
EoL-1	M1PqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXWxd5ZPUUN3ME21MlE4KG6P	NIDHU4FUSU6JRWK=
NCI-H720	NXnvS49VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJ4LkmyJI5O	NILwcXRUSU6JRWK=
NCI-SNU-5	NFr1OXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYj6elM4UUN3ME2yPE4yQSCwTR?=	M3jsOHNCVkeHUh?=
EW-3	M1TaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEG0T3NKSzVyPUS2MlA1KG6P	NUjDZVZpW0GQR1XS
HCC2218	Mn76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTPNlJoUUN3ME21NE42QSCwTR?=	M1y4N3NCVkeHUh?=
HuO-3N1	MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTV4LkC5JI5O	MmK2V2FPT0WU
DB	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXMW\|RwUUN3ME22NE46PiCwTR?=	MXzTRW5ITVJ?
HSC-4	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDzTWM2OD14MT61N{BvVQ>?	MkTvV2FPT0WU
DOK	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH71XFNKSzVyPUmzMlYzKG6P	MoL4V2FPT0WU
H9	M4fJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi0O3NKSzVyPUGzO{4zKG6P	NIPseoNUSU6JRWK=
NCI-H292	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHnTHpKSzVyPUG2Nk43PiCwTR?=	MorFV2FPT0WU
HSC-2	Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzXTWM2OD1zNkWuOVchdk1?	M3\aTHNCVkeHUh?=
LU-65	M2XDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1exOmlEPTB;MU[2MlYyKG6P	NF3y[o5USU6JRWK=
BV-173	NWX5OoI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTF6Nj61OUBvVQ>?	NH:0R2ZUSU6JRWK=
LB2241-RCC	M1fKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTF7ND65N{BvVQ>?	NXTD[ZZHW0GQR1XS
KG-1	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;NXmlEPTB;MkC0MlM1KG6P	MYDTRW5ITVJ?
CHL-1	M{XXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJyOD61NUBvVQ>?	NWLwSlRLW0GQR1XS
KYSE-140	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTJyOT65OkBvVQ>?	NVz3V2t{W0GQR1XS
DU-145	NHqyUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHlbZdKSzVyPUKxPU4xPCCwTR?=	MXjTRW5ITVJ?
EW-13	NInxTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nEb2lEPTB;MkK1MlEhdk1?	MlnWV2FPT0WU
KYSE-450	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTJ2Nz65NkBvVQ>?	Mm\WV2FPT0WU
CAL-72	NVr0ZVZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTJ4OD63N{BvVQ>?	NIrme2hUSU6JRWK=
MEG-01	M4\ueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDQTWM2OD1{N{[uO\|Yhdk1?	NHjCfmVUSU6JRWK=
HCE-T	M{fTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHOTWM2OD1{N{muO\|khdk1?	M4SzbHNCVkeHUh?=
NCI-SNU-1	M4PSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTJ6Mz6zNkBvVQ>?	NYLFNmllW0GQR1XS
CAL-27	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzzTWM2OD1{OEmuNFghdk1?	MmLuV2FPT0WU
BALL-1	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\CTWM2OD1{OUeuOFIhdk1?	M2XKZ3NCVkeHUh?=
SBC-1	M2DVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlqzTWM2OD1\|MEeuO\|khdk1?	MmfaV2FPT0WU
CAL-54	NFOyUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoG0TWM2OD1\|MUGuNlMhdk1?	MUHTRW5ITVJ?
TI-73	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTNzMj63OUBvVQ>?	NFPiXnBUSU6JRWK=
P12-ICHIKAWA	NInoSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7PTWM2OD1\|MkiuNFYhdk1?	NWXpS\|JDW0GQR1XS
ACHN	NV7I[oJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DPdWlEPTB;M{OxMlQhdk1?	M{XTNnNCVkeHUh?=
PC-14	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTN\|Mz60NUBvVQ>?	Mo\NV2FPT0WU
HCC1806	NX21OY9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{W3bGlEPTB;M{O3MlUyKG6P	MmG1V2FPT0WU
SK-MEL-24	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzKc\|VZUUN3ME2zN\|cvQDdibl2=	MlHFV2FPT0WU
A4-Fuk	NEPXTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonJTWM2OD1\|NUCuNFIhdk1?	NH\NbmhUSU6JRWK=
ECC10	NW\GToF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{i3WGlEPTB;M{WyMlk3KG6P	NWS4SpE{W0GQR1XS
KASUMI-1	MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTN4Nj63N{BvVQ>?	NULZUFVSW0GQR1XS
CAL-33	M17UXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;PUWNKSzVyPUO3NE46KG6P	MmHhV2FPT0WU
MDA-MB-175-VII	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTN5OD64PEBvVQ>?	NInRbI5USU6JRWK=
NUGC-3	NI\jTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTRyMT64NUBvVQ>?	Mn\yV2FPT0WU
KY821	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjhR5BKSzVyPUSwPE42PyCwTR?=	M{HOUHNCVkeHUh?=
CTB-1	NHTRb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmK0TWM2OD12MkSuOEBvVQ>?	NF3kUolUSU6JRWK=
DoTc2-4510	NV7VfXd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIL3UpBKSzVyPUS0Nk4yOiCwTR?=	NFfGTWFUSU6JRWK=
EFO-27	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXPcXhKSzVyPUS1OE44PCCwTR?=	M1\aTnNCVkeHUh?=
BPH-1	M2\OTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\ESos4UUN3ME20PVEvOTZibl2=	NU[4OYY3W0GQR1XS
KYSE-270	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4CzZmlEPTB;NEm4MlY2KG6P	NWjxOFJZW0GQR1XS
HO-1-N-1	MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXEcJd{UUN3ME21NFkvOjVibl2=	NXX0Rm9KW0GQR1XS
SK-MEL-1	NVzGTGlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzwTWM2OD13MUCuPVkhdk1?	NIXLcpRUSU6JRWK=
MOLT-13	M4rsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTVzND64NkBvVQ>?	NXTBRnZ6W0GQR1XS
TK10	M1rsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NViyZWZXUUN3ME21NVUvOTFibl2=	NYjnNVJnW0GQR1XS
HN	NVTLVHh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jNWGlEPTB;NUG3MlM5KG6P	MWXTRW5ITVJ?
SCC-15	NUfyTVRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PwU2lEPTB;NUK1MlY5KG6P	NEHwemxUSU6JRWK=
NCI-H358	M1TUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHxR\|RLUUN3ME21NlcvPjZibl2=	M3;lUnNCVkeHUh?=
KYSE-180	M13RV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIOw[ldKSzVyPUWzNE43OiCwTR?=	NYXkUpY3W0GQR1XS
NCI-H82	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHG1OXdKSzVyPUW0NE42KG6P	M2jSOHNCVkeHUh?=
NB7	NEDZbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LhUWlEPTB;NUS2MlMzKG6P	NIPpVXBUSU6JRWK=
DSH1	M1rLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;wO5lKSzVyPUW2Ok45QCCwTR?=	NVviNYpCW0GQR1XS
RS4-11	NHzoO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\yTWM2OD13NkiuOVkhdk1?	MXvTRW5ITVJ?
CAN	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MomyTWM2OD13OECuO\|Yhdk1?	MY\TRW5ITVJ?
Ca9-22	NY\YbJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jxfGlEPTB;NUi4MlY1KG6P	MUjTRW5ITVJ?
CAL-39	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEmyS\|VKSzVyPUW5Ok4{KG6P	MlT4V2FPT0WU
NCI-H1623	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnFOXlKSzVyPUW5PU4{PiCwTR?=	NEK3XVhUSU6JRWK=
FADU	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37hXmlEPTB;NkC0MlY6KG6P	M2nUTHNCVkeHUh?=
NB69	NYDONFZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUna[ZZnUUN3ME22NVQvOzVibl2=	NUS4RmY2W0GQR1XS
Ramos-2G6-4C10	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnyeXp5UUN3ME22NlEvPDZibl2=	MVHTRW5ITVJ?
LB1047-RCC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTsTWM2OD14MkWuNlkhdk1?	MojLV2FPT0WU
MV-4-11	NEHUfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXn3U2RuUUN3ME22NlcvPyCwTR?=	MmHIV2FPT0WU
DBTRG-05MG	M1ThRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1H6U2lEPTB;NkOyMlI5KG6P	NHT4VWZUSU6JRWK=
ME-180	M13DWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;nO4dKSzVyPU[zNk46KG6P	NVLrfph5W0GQR1XS
NBsusSR	NFHNNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;OTWM2OD14NE[uOVIhdk1?	NF[5fIRUSU6JRWK=
COR-L105	NG\CTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTZ4Mj61N{BvVQ>?	M33RTXNCVkeHUh?=
ETK-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnPWIdKSzVyPU[2Nk42QSCwTR?=	NYXKRXVRW0GQR1XS
L-363	NFv1d5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zYcWlEPTB;NkexMlk1KG6P	M3nMenNCVkeHUh?=
LU-134-A	M2r5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPlTWM2OD15MUmuNFkhdk1?	M2myTnNCVkeHUh?=
NCI-H1770	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HYRmlEPTB;N{KyMlQhdk1?	M3HuVXNCVkeHUh?=
HAL-01	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjQT3lKSzVyPUezOE44OSCwTR?=	MWrTRW5ITVJ?
COLO-684	NYDmT21NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFv3XopKSzVyPUe1N{4xOSCwTR?=	NUm0O3ppW0GQR1XS
TE-6	NGLINm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjjTWM2OD15NkSuN\|Ehdk1?	MV\TRW5ITVJ?
A431	MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zyeWlEPTB;N{iwMlA1KG6P	NGC5[XhUSU6JRWK=
LU-135	NXjVelhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTd6Mz6wN{BvVQ>?	NEe4NHFUSU6JRWK=
EC-GI-10	MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTd6OD61NkBvVQ>?	NFvkOVdUSU6JRWK=
TE-12	NGrQXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1q1XGlEPTB;OEKxMlEyKG6P	NWTIOHJSW0GQR1XS
LoVo	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkezTWM2OD16NUmuNFYhdk1?	NIruV\|dUSU6JRWK=
23132-87	M2rncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjSOXhvUUN3ME24OlQvOjhibl2=	Mne4V2FPT0WU
AU565	MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vafmlEPTB;OE[5MlYhdk1?	NITtXFhUSU6JRWK=
DEL	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4GwV2lEPTB;OEe3MlY2KG6P	NX7MNW5yW0GQR1XS
COR-L88	NID4cVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmW1TWM2OD16OEKuNlYhdk1?	Mn3RV2FPT0WU
NCI-H2126	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfUTWM2OD16OEKuPFMhdk1?	MoHrV2FPT0WU
CAPAN-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fDXGlEPTB;OEizMlI6KG6P	NWLtWWNtW0GQR1XS
BT-474	NEDYe3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M161RWlEPTB;OUO4MlE1KG6P	MlTrV2FPT0WU
BHY	NH;qRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MliyTWM2OD17N{WuOFghdk1?	MXnTRW5ITVJ?
HT-3	M322cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjObI1KSzVyPUm4Nk41OSCwTR?=	MXHTRW5ITVJ?
SK-NEP-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfSTWM2OD17OEmuOFQhdk1?	Mki0V2FPT0WU
MS-1	MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXLTWM2OD17OUSuOlkhdk1?	MoiwV2FPT0WU
DOHH-2	NG\Ldm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LlXWlEPTB;MT6wNFAzOSEQvF2=	NIrYd2NUSU6JRWK=
NCI-H1304	M330U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjqeXpKSzVyPUGuNFE3PDNizszN	NXyyT3NMW0GQR1XS
EM-2	M12zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37GdWlEPTB;MT6wN\|AyPiEQvF2=	Ml3mV2FPT0WU
MHH-PREB-1	M{\3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[wRYZkUUN3ME2xMlA5PDVzIN88US=>	MVnTRW5ITVJ?
KU-19-19	M1zrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPQfo5KSzVyPUGuNFg2PDFizszN	NXXDc\|dWW0GQR1XS
NCI-H1648	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTFwMUC2NVYh\|ryP	NIPVO4xUSU6JRWK=
MKN1	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPQNXpXUUN3ME2xMlIyQTh5IN88US=>	NGm5[5ZUSU6JRWK=
SNU-449	NVHpd2Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHqxUJhKSzVyPUGuNlIzODhizszN	MX3TRW5ITVJ?
OAW-42	NFzhfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rjTmlEPTB;MT6yO\|gzPSEQvF2=	NVzK[2ZMW0GQR1XS
769-P	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGm1d4VKSzVyPUGuNlc6OThizszN	MnjMV2FPT0WU
SW1088	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1[yR2lEPTB;MT6yPVYxPyEQvF2=	Mm\jV2FPT0WU
GCIY	NF;sZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\sT5F1UUN3ME2xMlMxOTN{IN88US=>	Mo\TV2FPT0WU
CTV-1	M2PjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXe5S25iUUN3ME2xMlMxQCEQvF2=	MkPtV2FPT0WU
NCI-H1092	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ywNGlEPTB;MT6zNFg2KM7:TR?=	NHnx[VVUSU6JRWK=
NKM-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmq2TWM2OD1zLkOyOVk4KM7:TR?=	Mn6zV2FPT0WU
NCI-H1650	NEPLV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;LVVJUUUN3ME2xMlM{PDh{IN88US=>	NVPwdG1iW0GQR1XS
SW954	M4PIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTFwM{SwOFgh\|ryP	Mn;jV2FPT0WU
SW48	NUP0W4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULSTGg{UUN3ME2xMlM3PjF6IN88US=>	M3vr[nNCVkeHUh?=
SK-N-DZ	NFnBbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojXTWM2OD1zLkO2PVQ4KM7:TR?=	NIj1e\|RUSU6JRWK=
KMOE-2	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2iydWlEPTB;MT6zPVgyPSEQvF2=	NEXYR2lUSU6JRWK=
NB5	M2XVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XkT2lEPTB;MT60NFg6PCEQvF2=	NGfWRVNUSU6JRWK=
CCRF-CEM	NXTwNGxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXrT4VKSzVyPUGuOFEyOSEQvF2=	NUXFVlEyW0GQR1XS
RH-1	M2\HXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4OwTmlEPTB;MT60NVE{PiEQvF2=	NGrQcFdUSU6JRWK=
NCI-H526	NWe5dJRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmC0TWM2OD1zLkSzPFI3KM7:TR?=	NXfiTYZ3W0GQR1XS
697	NFS2V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknXTWM2OD1zLkS0NVA1KM7:TR?=	Ml3SV2FPT0WU
J82	NWPNWmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHCTWM2OD1zLkS1O\|Y3KM7:TR?=	NXnMfWdjW0GQR1XS
BE-13	M2DnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXP0SZhxUUN3ME2xMlUxPjdzIN88US=>	NV\oTVN3W0GQR1XS
SAS	M3vKW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTFwNUG2NlIh\|ryP	NYXmWHRTW0GQR1XS
SCC-25	M4PaWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFwNUKzNlIh\|ryP	NIfBTmlUSU6JRWK=
LAMA-84	M{L0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1GxT2lEPTB;MT61N\|gyPSEQvF2=	NIfEWZlUSU6JRWK=
HSC-3	NEfyR\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3iyc2lEPTB;MT61OFM5KM7:TR?=	M4PZXnNCVkeHUh?=
BT-549	NXjPOW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTFwNUi3OFch\|ryP	MWTTRW5ITVJ?
ML-2	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHS2THdKSzVyPUGuOlQxOjlizszN	MXrTRW5ITVJ?
BB30-HNC	NVH0U3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTFwNki5O\|Ih\|ryP	NWjDZlVLW0GQR1XS
PANC-03-27	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTZV2pTUUN3ME2xMlcxOTN7IN88US=>	NVLveXFrW0GQR1XS
COLO-678	NITVb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3riRmlEPTB;MT63N\|Q1PCEQvF2=	NHTZd3lUSU6JRWK=
NCI-H1666	NGrt[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\1fmlEPTB;MT63OFcxPCEQvF2=	NX7DTG17W0GQR1XS
NCI-H209	NYLXeVM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFwN{eyOlkh\|ryP	MUDTRW5ITVJ?
EPLC-272H	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPRSJByUUN3ME2xMlg2PTR7IN88US=>	NIi0RWlUSU6JRWK=
OMC-1	NFu4fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTFwOUm4PFgh\|ryP	MV3TRW5ITVJ?
HCC70	NVvoZ\|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\4Z2lEPTB;Mj6wNFgyPSEQvF2=	M1zZNHNCVkeHUh?=
CAL-12T	NEfnTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HRVGlEPTB;Mj6wNVg3OSEQvF2=	MorTV2FPT0WU
TGBC24TKB	Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vHWmlEPTB;Mj6wNlk3OSEQvF2=	M13nS3NCVkeHUh?=
EKVX	MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYf4TJRiUUN3ME2yMlA1QTN7IN88US=>	NEPXSHVUSU6JRWK=
SW1116	M{jnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2i0fmlEPTB;Mj6wOlAxQSEQvF2=	M3PMO3NCVkeHUh?=
NCI-H2009	NULPRWFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HQe2lEPTB;Mj6wOlIyPCEQvF2=	NGm0WZZUSU6JRWK=
RPMI-8866	MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXldWZKSzVyPUKuNFg1QDFizszN	M1jNOHNCVkeHUh?=
KARPAS-45	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXf0UnE{UUN3ME2yMlEzPDd7IN88US=>	NVLnTlZwW0GQR1XS
RXF393	M3T2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnZXXlyUUN3ME2yMlE{ODN4IN88US=>	NF7mPXhUSU6JRWK=
786-0	NXHVVmV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nteWlEPTB;Mj6xPFQxPiEQvF2=	MWDTRW5ITVJ?
SCC-4	M3v0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHGxUW9KSzVyPUKuNlE4PzZizszN	MlHGV2FPT0WU
BT-20	NXTmc4VlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJwMk[3OFQh\|ryP	MlPaV2FPT0WU
A498	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7LTWM2OD1{LkK5OFE2KM7:TR?=	NWLBNGFFW0GQR1XS
IGROV-1	NF:wZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\SS2lEPTB;Mj6zNVI{PyEQvF2=	M2TXXHNCVkeHUh?=
JVM-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIKwUohKSzVyPUKuN\|Q3PDNizszN	MWHTRW5ITVJ?
NCI-H2170	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTJwM{S3PFMh\|ryP	NGjiO4NUSU6JRWK=
EW-18	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfleW9pUUN3ME2yMlM2PDdzIN88US=>	MXrTRW5ITVJ?
KU812	NWjkOJgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJwM{[3O\|kh\|ryP	MWnTRW5ITVJ?
NY	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTJwM{eyO{DPxE1?	NFXKPJRUSU6JRWK=
HTC-C3	NIflVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTJwNEKyOlch\|ryP	NIfONo5USU6JRWK=
CFPAC-1	M4n0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTJwNEO4OlQh\|ryP	Mk\FV2FPT0WU
HH	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHlTWM2OD1{LkS5PFU1KM7:TR?=	NWHWS4kzW0GQR1XS
MKN7	NETQbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTJwNkK3OFgh\|ryP	NXfZV5gxW0GQR1XS
TE-8	NXG4OZNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\MTWM2OD1{Lk[zOlU{KM7:TR?=	NYDsUYp[W0GQR1XS
MC-IXC	M3fnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7NZm9KSzVyPUKuOlQ1PTNizszN	NIPCWmdUSU6JRWK=
DMS-79	M4XpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmi4TWM2OD1{Lk[5Nlg1KM7:TR?=	NWXKTY5sW0GQR1XS
Detroit562	NGTXZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{j4b2lEPTB;Mj62PVg1PSEQvF2=	MkHJV2FPT0WU
HuP-T4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[0TWM2OD1{LkeyPFE5KM7:TR?=	NWfubI5KW0GQR1XS
QIMR-WIL	NYW5PFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJwN{W5OVIh\|ryP	NF;BS3NUSU6JRWK=
BB65-RCC	NYP0W4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGq2TWVKSzVyPUKuPFA4OTNizszN	NGPVcW9USU6JRWK=
PC-3	NWDQZ2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojvTWM2OD1{LkizN\|E4KM7:TR?=	M2SxTHNCVkeHUh?=
OVCAR-3	NFW5cWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTJwOEW1PVQh\|ryP	M2HjUHNCVkeHUh?=
KYSE-510	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTqd2dKSzVyPUKuPFY4QDZizszN	NEnkVI1USU6JRWK=
HC-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoW4TWM2OD1{Lkm0NFEzKM7:TR?=	Mn7GV2FPT0WU
NCI-H1693	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELqVGJKSzVyPUKuPVU5QTdizszN	NFH1[G9USU6JRWK=
DU-4475	NFjKeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonzTWM2OD1{Lkm5NFUzKM7:TR?=	NGC2bIJUSU6JRWK=
COLO-680N	NFi2PJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTNwMEC0PVUh\|ryP	NWnZPXJyW0GQR1XS
MN-60	MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjiRYdKSzVyPUOuNFQ6PzRizszN	M1;rZXNCVkeHUh?=
BCPAP	NYjUVZpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{THXWlEPTB;Mz6wPFI6PSEQvF2=	MnSzV2FPT0WU
647-V	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTNwMU[yNkDPxE1?	M1\GeHNCVkeHUh?=
HT-1376	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3e0emlEPTB;Mz6yNFUxPiEQvF2=	MnnMV2FPT0WU
NCI-H1793	NIPoXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTHTWM2OD1\|LkKxNFk5KM7:TR?=	NFG3T4RUSU6JRWK=
SW1463	MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fuXGlEPTB;Mz6yOlE6OiEQvF2=	NGrofZVUSU6JRWK=
NCI-H727	NVuwVZJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TidGlEPTB;Mz6zPFU5PCEQvF2=	NUj5OYpVW0GQR1XS
LB771-HNC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlq1TWM2OD1\|LkO5NVI3KM7:TR?=	MmTHV2FPT0WU
D-542MG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTNwNESyNlIh\|ryP	NFjqcotUSU6JRWK=
NTERA-S-cl-D1	NUW0d2s2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnGe3I6UUN3ME2zMlQ1QTV5IN88US=>	MWDTRW5ITVJ?
C8166	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHkSmdUUUN3ME2zMlQ3PTJzIN88US=>	NWTiToRqW0GQR1XS
639-V	Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXhcllKSzVyPUOuOVc4QTJizszN	MWfTRW5ITVJ?
TE-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFy0XnhKSzVyPUOuOVkyPjlizszN	MlzWV2FPT0WU
OAW-28	NYPGWJA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDaU4Z1UUN3ME2zMlU6PDJ4IN88US=>	NWTpWlFbW0GQR1XS
SK-LU-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mny2TWM2OD1\|Lk[wOlQ2KM7:TR?=	NFiyZmFUSU6JRWK=
CaR-1	MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIGzb4pKSzVyPUOuOlExPDhizszN	NVPOR5V4W0GQR1XS
A2780	M2T5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGn4ZndKSzVyPUOuOlQxQDlizszN	MVnTRW5ITVJ?
C2BBe1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzFPJhRUUN3ME2zMlY1PDB5IN88US=>	M3;OXHNCVkeHUh?=
SK-MES-1	NILrNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTNwNkS2NVQh\|ryP	NYTIboFnW0GQR1XS
PANC-10-05	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUD6V5hHUUN3ME2zMlczODd{IN88US=>	MmH3V2FPT0WU
J-RT3-T3-5	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTNwN{W0NFYh\|ryP	NF60TXZUSU6JRWK=
ES4	NF[2SVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW[yc2hRUUN3ME2zMlgzOjh4IN88US=>	M37sfHNCVkeHUh?=
NCI-H28	M4\TT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vCeWlEPTB;Mz64Nlk3OSEQvF2=	M2flOnNCVkeHUh?=
NCI-H1155	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjTTWM2OD1\|Lki0NVU6KM7:TR?=	NXvIPVJCW0GQR1XS
KURAMOCHI	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljWTWM2OD1\|Lki2NFU3KM7:TR?=	NF21W\|dUSU6JRWK=
NCI-H69	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPPTWM2OD1\|LkmwNVc5KM7:TR?=	M2LPVnNCVkeHUh?=
IST-MES1	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3r1ZWlEPTB;Mz65OFAzQSEQvF2=	MkT5V2FPT0WU
NH-12	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHztZmlKSzVyPUOuPVQyQDdizszN	NGnDe5RUSU6JRWK=
JVM-2	M2jvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rufmlEPTB;Mz65OFc2OiEQvF2=	NFnXTnhUSU6JRWK=
EW-16	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjve\|lKSzVyPUOuPVU2PzdizszN	NGHBWZBUSU6JRWK=
NCI-H441	NFzCfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Pm[2lEPTB;Mz65O\|AyPCEQvF2=	M17YSXNCVkeHUh?=
RCC10RGB	NGTpSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTRwMEGyOFYh\|ryP	M1;vVXNCVkeHUh?=
TCCSUP	NF\EbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLVTWM2OD12LkGxNFUh\|ryP	M{j6b3NCVkeHUh?=
HL-60	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfWVmRKSzVyPUSuNVIzPDFizszN	NHnVVXpUSU6JRWK=
EW-11	MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHu3[HlKSzVyPUSuNVMzPjFizszN	MlvpV2FPT0WU
KARPAS-299	M4PY[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFz0OGFKSzVyPUSuN\|ExOTNizszN	M3zucXNCVkeHUh?=
SNU-C2B	NHTGS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fVd2lEPTB;ND6zOFY5PiEQvF2=	NXzER3IyW0GQR1XS
LU-139	M4fZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTRwM{eyOFch\|ryP	M1S3dXNCVkeHUh?=
HCC1937	NWDzTWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmrvTWM2OD12LkO3PVk{KM7:TR?=	NVfOUmViW0GQR1XS
GR-ST	M4OzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Pte2lEPTB;ND60N\|E5KM7:TR?=	NX\1S3loW0GQR1XS
SK-OV-3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnvOG9KSzVyPUSuOFYxPDJizszN	NF;k[VVUSU6JRWK=
A172	M2OzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLMUJFKSzVyPUSuOVU2OjFizszN	Mny4V2FPT0WU
NB10	NEHPV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jjNWlEPTB;ND61PVc5OSEQvF2=	NVXTR\|hMW0GQR1XS
P30-OHK	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTRwOEG5Nlkh\|ryP	M2PyZXNCVkeHUh?=
KYSE-520	M2nqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\E[WRKSzVyPUSuPFgxOThizszN	M{DySXNCVkeHUh?=
KNS-62	NVXyTGcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{D1R2lEPTB;ND65NFgxPyEQvF2=	MXvTRW5ITVJ?
ES1	NF3Hd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLtVpJKSzVyPUSuPVYxOzVizszN	MVPTRW5ITVJ?
KOSC-2	NYmy[\|V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTRwOUm5OVkh\|ryP	NHn5[oJUSU6JRWK=
TE-9	M{\LfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTVwMEG1NlUh\|ryP	MYrTRW5ITVJ?
NCI-H1838	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrFV5BKSzVyPUWuNFIxPzZizszN	MXnTRW5ITVJ?
KP-N-YN	NYrXW3pjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlf5TWM2OD13LkGyOVkyKM7:TR?=	NYX1bVcxW0GQR1XS
ALL-PO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnMbIg2UUN3ME21MlIzPTh5IN88US=>	M1yycHNCVkeHUh?=
NOMO-1	NYjqeHB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrveFNQUUN3ME21MlI{OTd4IN88US=>	M1POUnNCVkeHUh?=
CGTH-W-1	MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknvTWM2OD13LkO4OVg1KM7:TR?=	MYXTRW5ITVJ?
ATN-1	NVqyPFE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7mZo14UUN3ME21MlQyOTh2IN88US=>	NH6wWm1USU6JRWK=
AGS	M17SW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\uUmNKSzVyPUWuOFk3OThizszN	NV2ySWpOW0GQR1XS
SW13	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnz1TWM2OD13LkWzNlY2KM7:TR?=	MWTTRW5ITVJ?
SW1990	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTVwNkKyPFUh\|ryP	NEiwWnhUSU6JRWK=
BFTC-905	NXfFd3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;UTWM2OD13Lk[1PFc5KM7:TR?=	MlnCV2FPT0WU
RMG-I	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHCTWM2OD13Lk[1PVQzKM7:TR?=	MlvnV2FPT0WU
HD-MY-Z	MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfHXJpKSzVyPUWuOlg2QDFizszN	NX36NVVVW0GQR1XS
HCC1187	NHnCTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLtTWM2OD13LkexNFMzKM7:TR?=	NYPOcJBSW0GQR1XS
HCC2998	M1rvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DtRmlEPTB;NT63NVg4PyEQvF2=	MoLOV2FPT0WU
RT-112	NG\HbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTjTWM2OD13LkmwNlQ2KM7:TR?=	MVjTRW5ITVJ?
CAKI-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLhUJV4UUN3ME22MlAxQTh3IN88US=>	NWfrNYh5W0GQR1XS
HDLM-2	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\zVlc5UUN3ME22MlAyPDh7IN88US=>	MU\TRW5ITVJ?
TE-10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\3ZlZQUUN3ME22MlA1QDN\|IN88US=>	NWjze\|kxW0GQR1XS
KE-37	M3PVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvxTWM2OD14LkC3NlU5KM7:TR?=	MkTFV2FPT0WU
RCM-1	NWLUdGZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULFeopWUUN3ME22MlA4PzF7IN88US=>	MV;TRW5ITVJ?
Mewo	M{PXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofWTWM2OD14LkGxOFg4KM7:TR?=	MnfWV2FPT0WU
L-428	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33PbWlEPTB;Nj6xPFA{PyEQvF2=	MmHZV2FPT0WU
8-MG-BA	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nyW2lEPTB;Nj6xPVM4QSEQvF2=	MlrQV2FPT0WU
SK-MEL-28	NXXPNFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fhUmlEPTB;Nj6yNFk3PyEQvF2=	M2LPcXNCVkeHUh?=
VA-ES-BJ	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzyR3FKSzVyPU[uN\|A1PjJizszN	MUXTRW5ITVJ?
CAL-120	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Hnc2lEPTB;Nj60OVE3OiEQvF2=	MlLrV2FPT0WU
GAMG	NXW1b3QyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTZwNUC2NkDPxE1?	MnjuV2FPT0WU
MSTO-221H	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTZwNUGxO{DPxE1?	Ml\DV2FPT0WU
GCT	NEm2VppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PMTmlEPTB;Nj61N\|M5PyEQvF2=	NUfBT4NYW0GQR1XS
SH-4	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LlVWlEPTB;Nj61PFg1PCEQvF2=	M1O3[3NCVkeHUh?=
Calu-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jLRmlEPTB;Nj62OVU3QCEQvF2=	NEDxPWxUSU6JRWK=
SK-HEP-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGK5enhKSzVyPU[uO\|E4PTNizszN	MVzTRW5ITVJ?
PFSK-1	MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETEeXdKSzVyPU[uO\|M1PzhizszN	NHGydXhUSU6JRWK=
NB12	M3rWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1uwV2lEPTB;Nj63PFQxPCEQvF2=	M1zjXXNCVkeHUh?=
A388	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfoNodKSzVyPU[uPFk2OiEQvF2=	MUnTRW5ITVJ?
KLE	NYLNeVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjzfm9KSzVyPU[uPVY2OTZizszN	NFLCN4ZUSU6JRWK=
TE-11	NHfaXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTdwMES5Olch\|ryP	MlXFV2FPT0WU
NCI-H2405	M1nkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkL6TWM2OD15LkC4N\|k{KM7:TR?=	MY\TRW5ITVJ?
OVCAR-4	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTdwMUWzOUDPxE1?	MXvTRW5ITVJ?
KP-N-YS	NGX4UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzYNZI5UUN3ME23MlE5OTRizszN	Mm\IV2FPT0WU
NOS-1	NWPU[2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mni0TWM2OD15LkK1PFI5KM7:TR?=	NV;YNIFTW0GQR1XS
DMS-114	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnn6TWM2OD15LkK5OlMyKM7:TR?=	M2D2fHNCVkeHUh?=
NCI-H2030	M3rCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfFT2Q6UUN3ME23MlM{Pjl6IN88US=>	MUPTRW5ITVJ?
HEL	NHfpNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPBZ5VKSzVyPUeuN\|c2OjFizszN	M4LDZXNCVkeHUh?=
CAL-62	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXucGZKSzVyPUeuN\|k5PjZizszN	M1\P[HNCVkeHUh?=
COLO-668	NUXxVXU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTdwNEO5Olch\|ryP	NWnofVNUW0GQR1XS
SKG-IIIa	NGDHb\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF6yRm9KSzVyPUeuOFU{QDFizszN	NV3seGhxW0GQR1XS
HCC1419	MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV[4Xm5RUUN3ME23MlQ3QDN\|IN88US=>	NIfLVINUSU6JRWK=
OS-RC-2	NYe0XoFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDYfmJ5UUN3ME23MlQ6QDl2IN88US=>	M1\LUHNCVkeHUh?=
COLO-829	M33hUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV65VW9tUUN3ME23MlY3PDZ\|IN88US=>	Mon1V2FPT0WU
NB13	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDWTWM2OD15LkiyOlY4KM7:TR?=	NILmSHJUSU6JRWK=
DK-MG	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvZTZBCUUN3ME23Mlg{OjBzIN88US=>	M1:1NHNCVkeHUh?=
SHP-77	NFv2ZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTuTWM2OD15Lki2OlU{KM7:TR?=	M3LONXNCVkeHUh?=
NCI-H661	NGHDd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljJTWM2OD16LkC1PFY4KM7:TR?=	NELJd45USU6JRWK=
AM-38	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITJVXpKSzVyPUiuNVYzQCEQvF2=	M4nWcnNCVkeHUh?=
VM-CUB-1	NHLnTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnntTWM2OD16LkG3NFI6KM7:TR?=	MYPTRW5ITVJ?
KYSE-70	NEHEelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRThwMUm3OlEh\|ryP	MoiwV2FPT0WU
5637	Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LtWGlEPTB;OD6zNVA2PSEQvF2=	MnfyV2FPT0WU
TGBC11TKB	NWC4d5JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fYWGlEPTB;OD60OlE3PCEQvF2=	M1GxSHNCVkeHUh?=
EGI-1	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\VcoJ1UUN3ME24MlYxODh6IN88US=>	Mnr3V2FPT0WU
D-392MG	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\GVINKSzVyPUiuOlYzOTRizszN	NFHyU2lUSU6JRWK=
A673	NGDQNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRThwNke2NVEh\|ryP	NGq0O2VUSU6JRWK=
COLO-792	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrqTWM2OD16Lke0PVQ3KM7:TR?=	MojvV2FPT0WU
NCI-H1792	M{XkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7VfVdKSzVyPUiuPFg6ODNizszN	MVnTRW5ITVJ?
LS-1034	NEfzZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\HTWM2OD16Lkm0OlUzKM7:TR?=	NXe5fJJWW0GQR1XS
D-566MG	NXTyUGxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3n3cmlEPTB;OT6wNVgyKM7:TR?=	NVLlfo94W0GQR1XS
NCI-H226	NHLzSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTlwMEmg{txO	MlTBV2FPT0WU
ChaGo-K-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTlwMUC1O\|kh\|ryP	M3jp[nNCVkeHUh?=
NCI-H2228	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYniZ\|lHUUN3ME25MlEyODhzIN88US=>	NXXs[nZxW0GQR1XS
RPMI-8226	M4i4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLTVFF6UUN3ME25MlEyOzB2IN88US=>	NGrpb4pUSU6JRWK=
BFTC-909	NXXKNpdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHzRY5KSzVyPUmuNVgzQTdizszN	NEfkRXFUSU6JRWK=
HPAF-II	M{DH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDSW\|ZKSzVyPUmuNlI2OThizszN	M2nSSXNCVkeHUh?=
Capan-2	NYq4OWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojvTWM2OD17LkSwNVA6KM7:TR?=	NE\rb21USU6JRWK=
IA-LM	NEfzdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1znPWlEPTB;OT60NVk3PiEQvF2=	MYXTRW5ITVJ?
KP-4	Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fZbmlEPTB;OT60PFg{QCEQvF2=	M4rkdnNCVkeHUh?=
A101D	NGLCZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13NZWlEPTB;OT61NVcyQSEQvF2=	NIHvdHdUSU6JRWK=
EFO-21	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTlwNUi3N\|Uh\|ryP	NUS5NnZjW0GQR1XS
C32	NH\5[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33LWWlEPTB;OT62N\|M1KM7:TR?=	NFnxRVRUSU6JRWK=
SW837	NEW2T2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTlwOES4NkDPxE1?	Mn3JV2FPT0WU
OCI-AML2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzYRmFKSzVyPUmuPFY6PiEQvF2=	MU\TRW5ITVJ?
NCI-H1355	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfzR2lYUUN3ME25Mlk1ODh6IN88US=>	NHrYXIJUSU6JRWK=
NCI-H2342	NX;hPIFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTFyLkCxOVUh\|ryP	NUn2VHpKW0GQR1XS
A204	NYDsc4w2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPuXpdGUUN3ME2xNE4xPDZ4IN88US=>	MXTTRW5ITVJ?
CAL-51	MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LBW2lEPTB;MUCuNFg4PyEQvF2=	NHzm[GRUSU6JRWK=
HCE-4	NF7C[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXOTWM2OD1zMD6xNVIzKM7:TR?=	M{D4cXNCVkeHUh?=
NCI-H810	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jEXmlEPTB;MUCuNVU6PyEQvF2=	MkL4V2FPT0WU
DJM-1	MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzzZ4s6UUN3ME2xNE4yPzN{IN88US=>	MoHuV2FPT0WU
SK-UT-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlraTWM2OD1zMD6yOVc1KM7:TR?=	MmHOV2FPT0WU
U031	NFzZPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLRTWM2OD1zMD6yOlg3KM7:TR?=	MmDaV2FPT0WU
YH-13	NYT3OpdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rJeGlEPTB;MUCuN\|A2PyEQvF2=	NIr6fXVUSU6JRWK=
K5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{G2eGlEPTB;MUCuN\|M6PSEQvF2=	MVvTRW5ITVJ?
HEC-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTFyLkSwPFEh\|ryP	M4PzO3NCVkeHUh?=
A2058	NFnpRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFyLkW0PVEh\|ryP	MnjzV2FPT0WU
SW962	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzVO2lKSzVyPUGwMlYzODRizszN	M3rh[nNCVkeHUh?=
VMRC-RCZ	NVz1XIdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7UTWM2OD1zMD62O\|Q6KM7:TR?=	Mk\aV2FPT0WU
D-336MG	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fU[mlEPTB;MUCuO\|AxPSEQvF2=	MoO2V2FPT0WU
LXF-289	NGLIZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\BUIlKSzVyPUGwMlc6PjdizszN	NF;BSmpUSU6JRWK=
SW900	NEHGSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrrboM1UUN3ME2xNE45OjJ6IN88US=>	MlW1V2FPT0WU
K-562	M1\IcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{faUGlEPTB;MUCuPFM6PSEQvF2=	NI[2PJJUSU6JRWK=
HCC38	NXHyXHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPUOnNKSzVyPUGwMlk4OTZizszN	MYHTRW5ITVJ?
SF-295	NU\LRWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTFyLkm5NFIh\|ryP	MVTTRW5ITVJ?
LB831-BLC	NFW1V4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3VTWM2OD1zMT6yOVU3KM7:TR?=	MWPTRW5ITVJ?
FTC-133	M2T3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHnWotKSzVyPUGxMlMxQDFizszN	NYLNOWFPW0GQR1XS
HCC1954	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7MTWM2OD1zMT60N\|Yh\|ryP	NEniU\|VUSU6JRWK=
GOTO	MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLSW2tKSzVyPUGxMlUzODZizszN	M3:5cnNCVkeHUh?=
LS-411N	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HaVGlEPTB;MUGuOlExOSEQvF2=	NEfYPXRUSU6JRWK=
RPMI-7951	M{Tsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[zdpVKSzVyPUGxMlY{PDhizszN	NFn3c4RUSU6JRWK=
NCI-H1299	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HMW2lEPTB;MUGuOlY1PyEQvF2=	NIPSV\|RUSU6JRWK=
MLMA	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTFzLk[5PVch\|ryP	NFPDc2xUSU6JRWK=
MMAC-SF	NXXKOpNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\5ZodKSzVyPUGxMlczPTJizszN	M4PTXXNCVkeHUh?=
UM-UC-3	M{LZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHGTWM2OD1zMT63OFIyKM7:TR?=	NY\0XnJyW0GQR1XS
SCC-9	NF:zUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zFNGlEPTB;MUGuPFE2OSEQvF2=	MkCyV2FPT0WU
HOS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILJSFRKSzVyPUGxMlg3QDNizszN	M3LORXNCVkeHUh?=
OE19	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoS0TWM2OD1zMT65N\|Y4KM7:TR?=	Mme0V2FPT0WU
Mo-T	NWPKPHZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLaZmtIUUN3ME2xNU46PTRzIN88US=>	MlzrV2FPT0WU
CAMA-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojxTWM2OD1zMj6xOlM{KM7:TR?=	Mn24V2FPT0WU
U-118-MG	NH24XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;2XlM2UUN3ME2xNk4zPDRzIN88US=>	NWDNOYJuW0GQR1XS
KS-1	MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NES3VFZKSzVyPUGyMlI5OzJizszN	NX2zV5NxW0GQR1XS
JAR	M1exWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HYcWlEPTB;MUKuN\|M3QSEQvF2=	NELzTpJUSU6JRWK=
ABC-1	Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nBcGlEPTB;MUKuN\|QyKM7:TR?=	NXTXOpFmW0GQR1XS
Daoy	MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTqTWM2OD1zMj60OVQzKM7:TR?=	MYnTRW5ITVJ?
C3A	MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjZN3dPUUN3ME2xNk42Pzh3IN88US=>	NGnRNJNUSU6JRWK=
GT3TKB	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXHdWt5UUN3ME2xNk43OzJ5IN88US=>	MmqzV2FPT0WU
DMS-273	M2[xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TLZWlEPTB;MUKuPFY{OyEQvF2=	NGrZWphUSU6JRWK=
G-361	M2j1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTF{LkmxNlkh\|ryP	MXXTRW5ITVJ?
RH-18	NInITYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2G5OmlEPTB;MUOuNlk3OiEQvF2=	NGHTO4FUSU6JRWK=
SN12C	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XybmlEPTB;MUOuN\|gxQCEQvF2=	Moe5V2FPT0WU
NCI-H1993	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\OVWlEPTB;MUOuOFI5PSEQvF2=	MXjTRW5ITVJ?
LOXIMVI	Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DaU2lEPTB;MUOuOlE2OSEQvF2=	NF\vNHNUSU6JRWK=
SK-PN-DW	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX[zXGNpUUN3ME2xN{45PDJ5IN88US=>	MkDZV2FPT0WU
KALS-1	MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrWdXF[UUN3ME2xN{45PTJ3IN88US=>	MWHTRW5ITVJ?
LAN-6	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTF2LkK1N{DPxE1?	MVzTRW5ITVJ?
A549	NVvlfYZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PQOmlEPTB;MUSuOFcyOiEQvF2=	NH\LXGZUSU6JRWK=
RD	M13GUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvufIZrUUN3ME2xOE41QDF\|IN88US=>	MlrWV2FPT0WU
TGBC1TKB	NIjCTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PkZ2lEPTB;MUSuOlYyPSEQvF2=	NWHRVFhMW0GQR1XS
NCI-H630	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2f3UWlEPTB;MUSuPVQ3PyEQvF2=	M2jTXHNCVkeHUh?=
MIA-PaCa-2	NEHVdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHjSpBKSzVyPUG0Mlk3QSEQvF2=	MknGV2FPT0WU
NCI-H1755	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LBZmlEPTB;MUSuPVk2OyEQvF2=	Mn\qV2FPT0WU
MOLT-4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\HTWM2OD1zNT6wOFk4KM7:TR?=	NWizcG1rW0GQR1XS
CW-2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zyT2lEPTB;MUWuNVQzOSEQvF2=	MXrTRW5ITVJ?
COLO-320-HSR	NXrFNo52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;TTWM2OD1zNT61N\|A4KM7:TR?=	NYHHXpBTW0GQR1XS
UMC-11	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXSOpRkUUN3ME2xOU44PTJ\|IN88US=>	NV\xV5lJW0GQR1XS
MCF7	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTF3LkixOFUh\|ryP	NGP6SnhUSU6JRWK=
NCI-H23	NIPuUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXP2Xm1TUUN3ME2xOU45PDN6IN88US=>	NWTDcFFzW0GQR1XS
HuCCT1	NFi3RXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlG2TWM2OD1zNT64O\|Qh\|ryP	MXPTRW5ITVJ?
MPP-89	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TpN2lEPTB;MUWuPVQyPyEQvF2=	M4DveXNCVkeHUh?=
HT55	NG\ncZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\KTWM2OD1zNT65OFc5KM7:TR?=	NXfUXGU5W0GQR1XS
no-11	NHfjU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGO4SHBKSzVyPUG1Mlk3PjNizszN	NX70XFZvW0GQR1XS
GP5d	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFj1VXhKSzVyPUG2MlIyQDdizszN	NHX6O4lUSU6JRWK=
BHT-101	NXP3R2N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fuTmlEPTB;MU[uNlQ{QSEQvF2=	NF7qVJhUSU6JRWK=
M059J	M2DXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjaUo5KSzVyPUG2MlI5PCEQvF2=	MXvTRW5ITVJ?
D-283MED	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTF4LkSyNFkh\|ryP	MUXTRW5ITVJ?
BEN	M4ThO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjEZYZKSzVyPUG2MlUyPTVizszN	Mn;kV2FPT0WU
LB373-MEL-D	NUDDbnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHjZVlKSzVyPUG2MlczOzJizszN	M1fvPHNCVkeHUh?=
MEL-HO	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfqTWM2OD1zNj64PFU1KM7:TR?=	NUfWW4E2W0GQR1XS
GI-ME-N	NEPZVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HsdmlEPTB;MU[uPVA{OiEQvF2=	NIPJN2RUSU6JRWK=
RKO	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3G5XmlEPTB;MUeuNFc1QCEQvF2=	M{jjUXNCVkeHUh?=
MZ2-MEL	M37BR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PtOmlEPTB;MUeuNVM{KM7:TR?=	NUfFeW4{W0GQR1XS
NCI-H1573	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTF5LkK4NlYh\|ryP	MYfTRW5ITVJ?
NCI-H1581	NYjTXoluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnsN2xOUUN3ME2xO{41PDFzIN88US=>	MnHCV2FPT0WU
NCI-H747	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7t[GhoUUN3ME2xO{42Ojl5IN88US=>	NELNToJUSU6JRWK=
SW1783	MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nXSGlEPTB;MUeuOlQyPSEQvF2=	MnnEV2FPT0WU
Calu-6	M{jleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTjTWM2OD1zNz62O\|gzKM7:TR?=	M{KxeHNCVkeHUh?=
SF268	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTF5Lk[5Olkh\|ryP	MYnTRW5ITVJ?
ES8	NFO1OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnG3TWM2OD1zNz64OVk{KM7:TR?=	NYDuUIR[W0GQR1XS
KM-H2	NYDwRWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\4eGlEPTB;MUeuPVQyOSEQvF2=	M2r3ZXNCVkeHUh?=
D-502MG	M3T5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYriPIJ6UUN3ME2xO{46QDB6IN88US=>	M{\VWXNCVkeHUh?=
HLE	NFvEbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTF6LkOxOFgh\|ryP	M1;iZnNCVkeHUh?=
SW982	NGDkTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk[xTWM2OD1zOD60NFc2KM7:TR?=	MXLTRW5ITVJ?
MDA-MB-361	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGO5d5lKSzVyPUG4MlU2QDhizszN	NWjSXVR1W0GQR1XS
NCI-H1563	MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf2UppiUUN3ME2xPE44OTJ2IN88US=>	MXLTRW5ITVJ?
MFE-280	NVX1PIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjwcVdKSzVyPUG4MlczQTNizszN	M1fBcnNCVkeHUh?=
U251	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rXdWlEPTB;MUiuO\|M1PyEQvF2=	M2[yOnNCVkeHUh?=
KNS-42	NHrOZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTF6LkiwNVUh\|ryP	NHvUZ2hUSU6JRWK=
U-266	NGG4WlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\MenlvUUN3ME2xPE45PjR7IN88US=>	MXrTRW5ITVJ?
OVCAR-8	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TjXGlEPTB;MUiuPVI4PiEQvF2=	MYTTRW5ITVJ?
MFH-ino	M2X1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTF6Lkm2Olkh\|ryP	Mlv5V2FPT0WU
D-263MG	NWnh[I96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;4SZJKSzVyPUG5MlAyPzJizszN	MlW3V2FPT0WU
NCI-H1437	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTF7LkC0Olch\|ryP	M1jW[3NCVkeHUh?=
NCI-H1048	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7kZVZ6UUN3ME2xPU4zOzJ4IN88US=>	MnLrV2FPT0WU
NCI-H446	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGG0T4VKSzVyPUG5MlM2QDlizszN	M1W4dnNCVkeHUh?=
NCI-N87	NX76cllFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXw[3l6UUN3ME2xPU42QTl{IN88US=>	MojpV2FPT0WU
WM-115	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DZRWlEPTB;MUmuOlc4PCEQvF2=	MVvTRW5ITVJ?
HuH-7	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTF7Lke0NlEh\|ryP	NVzPTFV{W0GQR1XS
NCI-H650	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\hdWlEPTB;MUmuO\|UxQCEQvF2=	MorJV2FPT0WU
TYK-nu	NVXtT3lPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTF7LkizO\|gh\|ryP	NXvKZ5BmW0GQR1XS
Becker	MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHj0colKSzVyPUG5Mlg2PDdizszN	MWPTRW5ITVJ?
BB49-HNC	M1\lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF7LkmyJO69VQ>?	M3OyWHNCVkeHUh?=
HGC-27	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJyLkGzPVQh\|ryP	MoPIV2FPT0WU
SiHa	NUfXS4NWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGqwWGRKSzVyPUKwMlM4OTJizszN	MULTRW5ITVJ?
LB2518-MEL	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTJyLkO3N\|kh\|ryP	MX7TRW5ITVJ?
TE-5	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPuTWM2OD1{MD63OFgzKM7:TR?=	NY\3N25mW0GQR1XS
IST-SL1	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTJyLke4O\|kh\|ryP	NYDNOWhZW0GQR1XS
A375	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTJzLkC1Olch\|ryP	M1nrO3NCVkeHUh?=
MC116	M{Lld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPsUHdKSzVyPUKxMlA4OjNizszN	NEO3TlZUSU6JRWK=
GI-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVGz[3FNUUN3ME2yNU4yPyEQvF2=	NXLnNZRYW0GQR1XS
HOP-62	NXPl[ZdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M322S2lEPTB;MkGuNlc5PCEQvF2=	NWLPUYh7W0GQR1XS
PA-1	M3jOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrONpFKSzVyPUKxMlI4QDdizszN	NVf0XpR[W0GQR1XS
HT	NGmyUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHwU4szUUN3ME2yNU41OzNzIN88US=>	NYPwOWZEW0GQR1XS
HUTU-80	NUizNlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTJzLkSzN\|Yh\|ryP	NHXleJBUSU6JRWK=
NCI-H1975	Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInjPXJKSzVyPUKxMlQ3OSEQvF2=	M4fmNnNCVkeHUh?=
GAK	M1;Zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTJzLkS5PUDPxE1?	NXHhS3MxW0GQR1XS
SK-N-AS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv0TWM2OD1{MT61OlE6KM7:TR?=	MXLTRW5ITVJ?
OE33	NEjibXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXITWM2OD1{MT62NFQ3KM7:TR?=	NEf5[ohUSU6JRWK=
YKG-1	MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIT3WVFKSzVyPUKxMlY2PDVizszN	NIX5PGJUSU6JRWK=
CAL-85	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2G5UmlEPTB;MkGuPVMxPSEQvF2=	MV7TRW5ITVJ?
NCI-H2347	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLOR5l5UUN3ME2yNU46PDJ6IN88US=>	M2DCNnNCVkeHUh?=
PANC-08-13	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTJ{LkCxNVkh\|ryP	NHTEd5FUSU6JRWK=
SK-N-FI	NUXncItCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHhcFlKSzVyPUKyMlMxPzRizszN	MYTTRW5ITVJ?
NEC8	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfmfI1KSzVyPUKyMlUxPzhizszN	MWDTRW5ITVJ?
AN3-CA	NHfPZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3THRWlEPTB;MkKuOlA5PCEQvF2=	NH3hXHlUSU6JRWK=
HuO9	NWL3fFhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fFc2lEPTB;MkKuO\|M6PiEQvF2=	NIDxdGVUSU6JRWK=
COLO-800	NUfVXHJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHNcYJKSzVyPUKyMlc3PTNizszN	NUXONGYyW0GQR1XS
HT-29	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfETWM2OD1{Mj64PFI{KM7:TR?=	M{HmdnNCVkeHUh?=
OC-314	M2HKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfETWM2OD1{Mj64PFQ2KM7:TR?=	NHKze4hUSU6JRWK=
G-401	NUexSGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;aU4lEUUN3ME2yN{4xPDZ{IN88US=>	MXnTRW5ITVJ?
Saos-2	M3fxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nBOWlEPTB;MkOuOVE5OiEQvF2=	NUDvc3FZW0GQR1XS
UACC-62	NIXKdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHsO\|VKSzVyPUKzMlU5OzNizszN	NYnOVI9jW0GQR1XS
D-247MG	M1uyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rlW2lEPTB;MkOuO\|k{QSEQvF2=	MlvIV2FPT0WU
COLO-741	M4PaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTJ\|Lkm1OlUh\|ryP	NH3iS4pUSU6JRWK=
ES3	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfQbZZKSzVyPUK0MlAxOjNizszN	MWjTRW5ITVJ?
LNCaP-Clone-FGC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzBbnVSUUN3ME2yOE4xOjFzIN88US=>	MlLmV2FPT0WU
SW1710	NEXB[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlq4TWM2OD1{ND6xOVA3KM7:TR?=	MWHTRW5ITVJ?
LU-99A	MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJ2LkG4OFEh\|ryP	NV3LdXY1W0GQR1XS
HOP-92	NV;2dHFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\ob2g4UUN3ME2yOE44OjVizszN	MUHTRW5ITVJ?
LS-123	M{TXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnThTWM2OD1{ND65OlE1KM7:TR?=	MXzTRW5ITVJ?
T84	NX7sPZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fKWGlEPTB;MkSuPVc3PSEQvF2=	MlTkV2FPT0WU
HCT-116	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHMR5VKSzVyPUK1MlQyQDZizszN	MonuV2FPT0WU
M14	NI\SNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml70TWM2OD1{NT60OFQ4KM7:TR?=	NH7scWFUSU6JRWK=
OCUB-M	M{PxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonyTWM2OD1{NT60OFU3KM7:TR?=	NV2xOFdSW0GQR1XS
MKN45	M1v4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVX3dJJSUUN3ME2yOU43OzF3IN88US=>	NVKwdVVMW0GQR1XS
LCLC-97TM1	M2PYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJ3LkeyPFUh\|ryP	NUXVfnRPW0GQR1XS
RVH-421	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\DTWlEPTB;MkWuPFE3OSEQvF2=	M3fIZXNCVkeHUh?=
NKS-81-FD	M1q4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTqTWM2OD1{NT65NFIyKM7:TR?=	NXPQO4E4W0GQR1XS
NCI-H596	M17wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfOcGRKSzVyPUK2MlA1QDdizszN	NFiyXHFUSU6JRWK=
GB-1	NGCzRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTj[WZKSzVyPUK2MlE5PzlizszN	NInJXFFUSU6JRWK=
ZR-75-30	M2foOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfwflNKSzVyPUK2MlIzQTdizszN	M{\HSXNCVkeHUh?=
U-2-OS	NIDqZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjuTWM2OD1{Nj6zO\|U4KM7:TR?=	MoS0V2FPT0WU
HuP-T3	NG\tNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXf3UI44UUN3ME2yOk43OTB{IN88US=>	NGfWUJVUSU6JRWK=
MOLT-16	MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfxTWM2OD1{Nj62NVY3KM7:TR?=	MlTGV2FPT0WU
U-87-MG	NIXHWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;FTWM2OD1{Nj63OFM5KM7:TR?=	MmXhV2FPT0WU
8505C	M13hOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHFOIdKSzVyPUK2MlkyOjZizszN	MmKxV2FPT0WU
SK-MEL-3	NFPJfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTZSXJKSzVyPUK2Mlk5OjhizszN	Ml3GV2FPT0WU
COLO-824	Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTJ5LkKxPVUh\|ryP	M3rab3NCVkeHUh?=
EW-1	M1\LWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvJ[2NKSzVyPUK3MlM2PTRizszN	M1zOdXNCVkeHUh?=
UACC-257	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvRTWM2OD1{Nz6zPFA1KM7:TR?=	NWPuN4lSW0GQR1XS
Hs-578-T	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHj5XYxKSzVyPUK3MlUzQTlizszN	NIHR[WFUSU6JRWK=
UACC-893	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknlTWM2OD1{Nz62OlMyKM7:TR?=	MnvBV2FPT0WU
MHH-NB-11	NGfs[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;H[mlEPTB;MkeuPFAxPyEQvF2=	NVXHWWNTW0GQR1XS
KYSE-410	NEK1OlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJ6LkK3O\|kh\|ryP	NGW0eWVUSU6JRWK=
SF126	MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PZcmlEPTB;MkiuO\|Q{PSEQvF2=	MlLnV2FPT0WU
HT-144	M3XJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIn3S5ZKSzVyPUK5MlM{PjJizszN	MmLrV2FPT0WU
SW1573	MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTJ7LkO1NFkh\|ryP	MUXTRW5ITVJ?
SW620	NUfIU28xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjOTWM2OD1{OT6zOlQyKM7:TR?=	NYDqXm9bW0GQR1XS
SCH	NYq1OZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\4dZNKSzVyPUK5Mlg5OzFizszN	MYfTRW5ITVJ?
EW-22	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTNyLkG5Olkh\|ryP	M{LYb3NCVkeHUh?=
H4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvKbJh[UUN3ME2zNE41PjV2IN88US=>	MnHlV2FPT0WU
CAS-1	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTJd496UUN3ME2zNE44QDV7IN88US=>	MmGxV2FPT0WU
MG-63	Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTNyLki0O\|gh\|ryP	M2frUnNCVkeHUh?=
MDA-MB-415	M1rOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTNzLkG3OVMh\|ryP	NVPzVGhbW0GQR1XS
NCI-H1395	NGLTV\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;tUYFKSzVyPUOxMlI{OjhizszN	NGr5SY9USU6JRWK=
Ca-Ski	NELmTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXraWlJbUUN3ME2zNU4{OTd5IN88US=>	M2TJSHNCVkeHUh?=
BxPC-3	M1;vemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjGXGFKSzVyPUOxMlM4OjlizszN	MUnTRW5ITVJ?
A3-KAW	NF21N2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTNzLkS0O\|Eh\|ryP	M2\NUHNCVkeHUh?=
T-24	M1;Bcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnz1TWM2OD1\|MT63N\|YzKM7:TR?=	MVLTRW5ITVJ?
NCI-H2029	NUfKToZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[1TWM2OD1\|MT63O\|Y2KM7:TR?=	MmXpV2FPT0WU
YAPC	NE\MbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLvN4tiUUN3ME2zNk4xPDB5IN88US=>	MVfTRW5ITVJ?
SK-MEL-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTN{LkC1NkDPxE1?	MlzRV2FPT0WU
LS-513	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXxWmdjUUN3ME2zNk4yOTh5IN88US=>	M3\I[nNCVkeHUh?=
AsPC-1	NIHoPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XvVWlEPTB;M{KuN\|YxPSEQvF2=	NIrUUIpUSU6JRWK=
KYSE-150	MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fTSmlEPTB;M{KuN\|c4OyEQvF2=	Mn;IV2FPT0WU
NCI-H520	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PtdGlEPTB;M{KuOFQ5OiEQvF2=	MmT5V2FPT0WU
JEG-3	NGnrRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFy0dm1KSzVyPUOzMlA6PzFizszN	MUDTRW5ITVJ?
GMS-10	NHT6eHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTN\|LkOwNFQh\|ryP	MnnoV2FPT0WU
HT-1080	M4fObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{X4TWlEPTB;M{OuN\|kh\|ryP	MX;TRW5ITVJ?
NCI-H1651	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTN\|LkO5OkDPxE1?	NFPJdmZUSU6JRWK=
NCI-H2122	NVy1Xmd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTN\|LkW1O\|Qh\|ryP	M1LtcXNCVkeHUh?=
ES5	NYHkSFM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3exVWlEPTB;M{OuO\|I6OiEQvF2=	NH7oSXdUSU6JRWK=
8305C	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXJbphKSzVyPUOzMlk6OzdizszN	NVi1fHJiW0GQR1XS
KM12	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDLeZFKSzVyPUO0MlA1PzhizszN	MUHTRW5ITVJ?
HCT-15	MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGX6Z2NKSzVyPUO0MlEzPyEQvF2=	MWjTRW5ITVJ?
OVCAR-5	NVjrPGFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjmTWM2OD1\|ND6yNVgzKM7:TR?=	M3S2ZXNCVkeHUh?=
NCI-H2291	NUnKRYxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\ySGlEPTB;M{SuNlQ4OiEQvF2=	Mlm5V2FPT0WU
CP50-MEL-B	M3jJTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTETWM2OD1\|ND62OVkzKM7:TR?=	MnnZV2FPT0WU
C-33-A	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTN2Lk[4OVch\|ryP	MlHDV2FPT0WU
NCI-H2452	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTN2Lke4PFIh\|ryP	MWjTRW5ITVJ?
MDA-MB-157	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTN2LkixPVMh\|ryP	NVixSHFVW0GQR1XS
LN-405	MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHzVY1nUUN3ME2zOU41OzB6IN88US=>	M2G2[3NCVkeHUh?=
MDA-MB-231	M13pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXvXmlKSzVyPUO1MlUxPTRizszN	M{f4c3NCVkeHUh?=
EW-24	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTN3Lk[zN\|Uh\|ryP	M4[1N3NCVkeHUh?=
MKN28	M{TMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLlfnJKSzVyPUO1MlgzOzZizszN	NX2y[3ZGW0GQR1XS
KINGS-1	M1P5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTN3Lki0N\|Qh\|ryP	NWTVSWxvW0GQR1XS
LC-2-ad	NXLHcHhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2K1SWlEPTB;M{[uOlk6KM7:TR?=	NFmySXpUSU6JRWK=
IGR-1	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTN4LkewO\|Uh\|ryP	MVPTRW5ITVJ?
SW626	NF\vc\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofpTWM2OD1\|Nz6wOFE4KM7:TR?=	NFy5ZWhUSU6JRWK=
ONS-76	NWDGTlVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTN5LkGzNFkh\|ryP	MljMV2FPT0WU
T98G	NEK1R5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLnbpZVUUN3ME2zO{45PjN3IN88US=>	NG\1WWlUSU6JRWK=
NB14	M1SyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2GzemlEPTB;M{iuOFU1PCEQvF2=	NVTMSYhnW0GQR1XS
D-423MG	NGXJeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIW0UWhKSzVyPUO4MlQ5PjlizszN	NVPBW5B7W0GQR1XS
NCI-H510A	NUPxXVFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTN6Lk[0OVEh\|ryP	MkjIV2FPT0WU
NMC-G1	MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3qyfmlEPTB;M{iuO\|IzOiEQvF2=	NUfOV2hIW0GQR1XS
SW948	NF:3VZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LtNGlEPTB;M{iuPFk1QSEQvF2=	M4PVOHNCVkeHUh?=
MFM-223	M2X0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHuTWM2OD1\|OD65OFMyKM7:TR?=	MVPTRW5ITVJ?
PAN1	NFXmR25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37HXWlEPTB;M{iuPVkyQSEQvF2=	MnTIV2FPT0WU
MZ7-mel	NWKxbIxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTN7LkGxPVkh\|ryP	NHWwSWZUSU6JRWK=
COLO-679	MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHDTYc4UUN3ME2zPU46PzB6IN88US=>	NUHXNXZiW0GQR1XS
SW872	MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTRyLkKwN\|Eh\|ryP	M3m5NnNCVkeHUh?=
HT-1197	M4HZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fGVmlEPTB;NECuNlg3QSEQvF2=	NX21e4plW0GQR1XS
ES6	NWPZXXczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHDblBwUUN3ME20NE41PTV{IN88US=>	NYHZRWZIW0GQR1XS
SNU-387	MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\kTWM2OD12MD64NlM5KM7:TR?=	M3zSeXNCVkeHUh?=
T47D	NXHT[HA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTRzLkCxPVIh\|ryP	MojDV2FPT0WU
G-402	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTRzLkC4NFkh\|ryP	NYTReodrW0GQR1XS
MZ1-PC	M4fU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7NVVgyUUN3ME20NU45OSEQvF2=	MlzTV2FPT0WU
SW1417	Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofJTWM2OD12Mj6zNFMh\|ryP	MlzUV2FPT0WU
RERF-LC-MS	NETCSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoT4TWM2OD12Mj61NFg4KM7:TR?=	MlXoV2FPT0WU
SF539	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vRVGlEPTB;NEKuOVUzQSEQvF2=	MXHTRW5ITVJ?
ESS-1	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzZXJlKSzVyPUSzMlU2PThizszN	NV7SSmVlW0GQR1XS
RO82-W-1	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHuU4xzUUN3ME20N{43OTV\|IN88US=>	NGjUVHlUSU6JRWK=
S-117	NVW3TI1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fYcmlEPTB;NEOuOlk2QCEQvF2=	NGSzVmNUSU6JRWK=
SW756	M{fKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfqOXp2UUN3ME20N{45OjR{IN88US=>	MVvTRW5ITVJ?
CP66-MEL	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYD0XYVFUUN3ME20OU44OTR\|IN88US=>	MWDTRW5ITVJ?
H-EMC-SS	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTR3Lke2PVMh\|ryP	M3nkVnNCVkeHUh?=
NCI-H2052	NHzGPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vRZ2lEPTB;NEWuPVAzPyEQvF2=	NEnNN49USU6JRWK=
SW684	MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTR5LkCwPFEh\|ryP	Mn3uV2FPT0WU
HCC1569	NITsZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzjTVhKSzVyPUS3MlE3PThizszN	MYLTRW5ITVJ?
KGN	NXLUNXM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTR5LkOzNVEh\|ryP	M4TuT3NCVkeHUh?=
LCLC-103H	Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTR5LkS0NFQh\|ryP	MmKyV2FPT0WU
SW780	M3:2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnlTWM2OD12Nz62N\|UyKM7:TR?=	M{X3d3NCVkeHUh?=
NCI-H1703	NH:2bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Szb2lEPTB;NEiuN\|M2OiEQvF2=	M3HkVXNCVkeHUh?=
HCC1395	NW\Se\|ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HvNGlEPTB;NEiuO\|Q{OiEQvF2=	Mom0V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]	+ Expand Cell lines: NR6, NR6M and NR6W cells Concentrations: 0-2 μM Incubation Time: 72 hours Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay. (Only for Reference)
Animal Research:^[3]	+ Expand Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells. Formulation: 0.5% polysorbate Dosages: 100 mg/kg Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days (Only for Reference)

Cell Research:^[1]

+ Expand

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

+ Expand

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation: 0.5% polysorbate
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804100	Unknown status	--	Carcinoma Non-Small-Cell Lung\|Bronchial Neoplasms\|Carcinoma Bronchogenic\|Lung Diseases\|Lung Neoplasms	Wenzhou Medical University	May 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 189 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 189 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)